Senseonics Eversense 365 Glucose Monitor Cleared in the U.S.
Exelixis Unveils Additional Data on Cabometyx for Neuroendocrine Tumors
Cantor Fitzgerald Reiterates Neutral on Gilead Sciences, Maintains $70 Price Target
Gilead Sciences Analyst Ratings
Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections
Moderna Was Most Shorted S&P 500 Healthcare Stock in August for Second Consecutive Month